Published in Lab Business Week, March 2nd, 2008
The vaccine will utilize DelSite's proprietary GelVac(TM) nasal powder delivery platform, which offers many distinct advantages over traditional vaccine delivery systems: (1) easy, needle-free, self-administration,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.